Clinical Trials Logo

Myositis clinical trials

View clinical trials related to Myositis.

Filter by:

NCT ID: NCT02317094 Completed - Clinical trials for Sporadic Inclusion Body Myositis

Blood-flow Restricted Exercise in Inclusion Body Myositis

Start date: January 2015
Phase: N/A
Study type: Interventional

This study evaluates the effects of a low-intensity blood-flow restricted exerciser protocol on patient reported physical function, in patients with sporadic inclusion body myositis. The study is designed as a parallel group randomized controlled trial with a treatment group and a control group.

NCT ID: NCT02267005 Completed - Clinical trials for Juvenile Dermatomyositis

The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis

Start date: March 2015
Phase: N/A
Study type: Interventional

This project will bring together a multidisciplinary team of pediatric rheumatologists, neurologists, metabolic geneticists and exercise physiologists to determine the effect of creatine (CR) supplementation on muscle function and muscle metabolism in children with Dermatomyositis (DM). The investigators propose using well-established exercise testing techniques as well as new, powerful exercise imaging protocols in order to better delineate the effects of CR on muscle pathophysiology in a non-invasive way. Evidence from this study will provide information regarding the effect of creatine supplementation on muscle function in DM. Improvements in muscle function and fatigue through CR use may also contribute to an improvement in quality of life and have significant clinical implications for the treatment of children with DM.

NCT ID: NCT02250443 Completed - Clinical trials for Sporadic Inclusion Body Myositis (sIBM)

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

BYM338
Start date: March 11, 2014
Phase: Phase 2/Phase 3
Study type: Interventional

This study is an open-label, long-term study for those patients who participated in the prior proof-of-concept protocol, in which the preliminary efficacy for BYM338 in patients with sIBM was demonstrated after a single 30 mg/kg i.v. dose of BYM338. This study is designed to confirm the efficacy, safety and tolerability of BYM338 in sIBM with long-term dosing. However due to lack of efficacy in patients with sIBM, the study was terminated early.

NCT ID: NCT02116166 Completed - Sarcopenia Clinical Trials

Skeletal Muscle Inflammation, Oxidative Stress and DNA Repair in Age-Related Sarcopenia

Start date: May 2014
Phase:
Study type: Observational

The purpose of this research study is to investigate how and why the loss of muscle mass occurs with aging. Tissue collected from young subjects will be compared to previously collected tissue from elderly subjects, as well as previously collected data on muscle function/mass to further investigate cellular and molecular pathways that have recently been shown to be important for the aging process in muscle. The Principal Investigator (PI) and the study team will look for specific proteins (called biomarkers) that can be present in the muscle tissue in various amounts in different individuals. This study will increase the investigators understanding of the processes of muscle atrophy (loss of mass) and functional loss at older age and will help to find new treatments and interventions aimed at improving the quality of life and independence of America's rapidly expanding elderly population.

NCT ID: NCT01931644 Completed - Breast Cancer Clinical Trials

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

Start date: July 2013
Phase:
Study type: Observational

We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research. We make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location or ability to travel.

NCT ID: NCT01925209 Completed - Clinical trials for Sporadic Inclusion Body Myositis

Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

RESILIENT
Start date: September 26, 2013
Phase: Phase 2/Phase 3
Study type: Interventional

This study evaluated the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function, muscle strength, and mobility in patients with sporadic inclusion body myositis (sIBM).

NCT ID: NCT01862926 Completed - Clinical trials for Interstitial Lung Disease

Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD

RECITAL
Start date: November 2014
Phase: Phase 2/Phase 3
Study type: Interventional

Interstitial lung disease (ILD) is characterised by inflammation and scarring of the lung and is the leading cause of death in patients with systemic sclerosis, and contributes significantly to morbidity and mortality in many other connective tissue diseases (CTDs) such as polymyositis/dermatomyositis and mixed connective tissue disease. When ILD is extensive and/or progressive, immunosuppressive medication is often required to stabilize lung disease and alleviate symptoms. Current standard care for CTD associated ILD is extrapolated from studies performed in individuals with systemic sclerosis and comprises low dose corticosteroids and intravenous cyclophosphamide followed by oral azathioprine. In some individuals even this intensive immunosuppression is insufficient to prevent deterioration, and in a significant minority of affected individuals this results in respiratory failure and death. Rituximab has recently been reported as an effective 'rescue therapy' for stabilizing and even improving ILD in this patient group. Based on observations gained from this experience, the investigators believe that rituximab is a potential important alternative to current best therapy for this patient group. This study has therefore been initiated to evaluate the efficacy of rituximab (compared with standard therapy) in patients with progressive CTD related ILD.

NCT ID: NCT01790178 Completed - Muscular Dystrophy Clinical Trials

Ultrasound in Muscle Biopsy

Start date: February 2013
Phase: N/A
Study type: Observational

The objective of the proposed study is to evaluate the clinical utility of muscle ultrasonography for improving the diagnostic yield and safety of core muscle biopsy. Our facility currently uses core (needle) biopsy to obtain muscle samples in patients 18 years old or older. Currently, there is no imaging tool used to guide the actual biopsy. As muscle biopsy is an invasive and potentially painful procedure, improving the diagnostic yield of this test is important.

NCT ID: NCT01734369 Completed - Dermatomyositis Clinical Trials

Environmental Risk Factors for Myositis in Military Personnel

Start date: March 13, 2014
Phase:
Study type: Observational

Background: - Myositis is a rare disease in which the body s immune cells attack the muscle tissue. It can cause muscle weakness, swelling, and pain. It can develop in people with no history of muscle problems. Environmental exposures may determine who develops myositis. Genes may also affect development of the disease. - Some people who serve in the military develop myositis. However, other military personnel do not. Researchers want to compare military personnel with and without myositis. They will look for common factors that might have led to the disease. Objectives: - To study environmental risk factors for myositis in military personnel. Eligibility: - Military personnel who developed myositis during their period of service. - Healthy military personnel who do not have myositis or another autoimmune disease. Design: - Participants will have a physical exam and medical history. - Participants will fill out forms about environmental exposures, particularly while in the military. The questions will ask about past infections, vaccines and medications, and personal habits. They will also ask about participants occupations during military service and their deployments. - Participants will also provide blood samples for study. - No treatment will be provided as part of this study.

NCT ID: NCT01702870 Not yet recruiting - Myositis Clinical Trials

Diagnostic Accuracy of MR in Myositis

Start date: November 2012
Phase: N/A
Study type: Observational

A prospective observational study to determine the effectiveness of magnetic resonance (MR) imaging in the diagnosis and monitoring of idiopathic myopathy in adult humans.